03 July 2017
Reporter: Barney Dixon
Canadian Supreme Court rips up promise doctrine
The Canadian Supreme Court has ripped up the country’s controversial ‘promise doctrine’ and upheld AstraZeneca’s heartburn drug patent as valid in its case against Apotex.

Apotex attempted to sell a generic version of AstraZeneca’s heartburn drug, Nexium, to which AstraZeneca responded with a patent infringement lawsuit.

Canada’s Federal Court of Appeals held that AstraZeneca’s patent for the drug was “invalid for lack of utility because, applying the promise of the patent doctrine, it promised more than it could provide”.

The dispute then went to the Supreme Court, which ruled that the promise doctrine is “not the correct method of determining whether the utility requirement under Section 2 of the Canadian Patent Act is met”.

“The promise doctrine is incongruent with both the words and the scheme of the Patent Act.”

The US Chamber of Commerce’s Global Intellectual Property Center (GIPC) welcomed the decision, with vice president of international intellectual property policy, Patrick Kilbride, describing the “restrictive approach” of the doctrine as “making it difficult to obtain or defend a life sciences patents in Canada”.

“Today, the Supreme Court has begun to restore much-needed clarity and confidence that biopharmaceutical innovators will be afforded equal protections under the law,” he said. “This ruling sends an important signal that Canada is open for the business of innovation.”

According to the GIPC, since the creation of the promise doctrine in 2005, 26 patents that covered 22 innovative medicines have been overturned.

Earlier this year, Eli Lilly lost its North American Free Trade Agreement (NAFTA) dispute with Canada over the doctrine.

Eli Lilly claimed that the doctrine contravened Canada’s NAFTA obligations, but a panel said it didn’t amount to a denial of justice warranting investor-state arbitration.

At the time, Kilbride said the doctrine “dramatically undermines legal certainty for medical innovators in Canada”.

More news
The latest news from IPPro Patents
Join Our Newsletter

Sign up today and never
miss the latest news or an issue again

Subscribe now
Stryker’s award increases to $248.7 million
21 July 2017 | Michigan | Reporter: Mark Dugdale
A US district court has increased the sum that medical device maker Zimmer must pay to rival Stryker, following the Supreme Court’s enhanced damages ruling in the litigation
Congressmen Issa and Goodlatte hit out at Judge Gilstrap
20 July 2017 | Washington DC | Reporter: Mark Dugdale
Two members of the House judiciary committee have criticised Judge Rodney Gilstrap for his interpretation of TC Heartland v Kraft Foods, going as far as to suggest that he is putting the needs of the Eastern District of Texas above serving justice
Broad Institute to pool CRISPR patents
20 July 2017 | Massachusetts | Reporter: Barney Dixon
The Broad Institute of MIT and Harvard have entered discussions to create a CRISPR-Cas9 joint patent pool, coordinated by MPEG LA
PatSnap partners with GreyB
20 July 2017 | London | Reporter: Barney Dixon
Intellectual property analytics company PatSnap has entered into a strategic alliance with technology consulting and research firm GreyB
Foley & Lardner boosts IP practice
20 July 2017 | California | Reporter: Barney Dixon
Foley & Lardner has added Duane Mathiowetz and Rick Chang to its San Francisco and Silicon Valley offices
BakerHostetler hires life sciences expert
20 July 2017 | Ohio | Reporter: Barney Dixon
Beverly Lyman has joined BakerHostetler’s intellectual property practice as partner
Eli Lilly maintains patent for erectile dysfunction drug
20 July 2017 | Virginia | Reporter: Mark Dugdale
Eli Lilly has agreed settlements with a group of generics companies to secure the exclusivity of Cialis until September 2018